AroCell
0.384
SEK
0 %
AROC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
0%
-5.42%
-26.86%
-4%
-12.13%
-12.73%
-52.17%
-67.93%
-83.88%
AroCell specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. AroCell targets patient groups in different parts of the world. The head office is in Stockholm.
Read moreMarket cap
88.46M SEK
Turnover
64.06K SEK
Revenue
43.04M
EBIT %
-138.89 %
P/E
-
Dividend yield-%
-
Financial calendar
19/2
2025
Annual report '24
7/5
2025
Interim report Q1'25
21/8
2025
Interim report Q2'25
ShowingAll content types
AroCell’s Tumor Marker TPS to be introduced on a leading Japanese IVD company´s new Automated CLIA Platforms in China
En ny studie påvisar nyttan av användningen av UBC® Rapid vid uppföljning av patienter med blåscancer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools